# UCB Type: Company (UCB.BR) Source: GetYourBrief — https://getyourbrief.com/entity/ucb Canonical HTML page: https://getyourbrief.com/entity/ucb ## Timeline - **2027**: Phased Hiring — Recruitment for specialized engineering and scientific roles is expected to ramp up as construction nears completion. - **2026-12-31**: Profitability Target — Antengene aims to achieve its first full year of profitability. - **2026-Q3**: Anticipated Groundbreaking — Expected commencement of construction for the multi-billion dollar manufacturing site. - **2026-04-01**: AACR 2026 — Antengene scheduled to present data on next-generation ADCs and TCEs. - **2026-03-31**: Clinical Filings Target — Antengene plans to submit CTAs for ATG-201 in China and Australia by the end of Q1 2026. - **2026-03-24**: Investment Announcement — UCB officially announces the $2 billion investment and 330-job creation plan for suburban Atlanta. - **2026-03-20**: 2025 FY Results — Company announces full-year results and confirms shift toward 2026 profitability. - **2026-03-04**: Investor Briefings — Antengene hosts conference calls in Chinese and English to discuss the UCB partnership. - **2026-03-04**: Investor Briefings — Antengene hosts dual-language conference calls to discuss the UCB partnership and pipeline impact. - **2026-03-04**: UCB Partnership — Antengene enters into a global license agreement with UCB for ATG-201 for $60M upfront. - **2026-03-03**: Global License Agreement — Antengene and UCB announce exclusive worldwide licensing deal for ATG-201. - **2026-03-03**: Global License Agreement — Antengene and UCB announce the $1.1B+ licensing deal for ATG-201. - **2026-Q1**: Regulatory Filings — Planned submission of clinical trial applications for ATG-201 in China and Australia. ## Recent coverage (7 stories, network-wide) ### UCB Commits $2B to Atlanta Manufacturing Hub to Fuel U.S. Growth 2026-03-24 23:54:36 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2 Belgian biopharma leader UCB has announced a massive $2 billion investment to construct a new manufacturing facility in suburban Atlanta, Georgia. The project is expected to create 330 high-tech jobs and significantly enhance the company's production capacity for its growing immunology and neurology portfolios. Full story: https://getbiobrief.com/story/ucb-atlanta-manufacturing-expansion-2-billion ### UCB Commits $2B to Atlanta Manufacturing Hub Amid Biologic Growth 2026-03-24 23:54:02 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2 Belgian biopharma giant UCB has announced a massive $2 billion investment to establish a new manufacturing plant in suburban Atlanta, creating 330 high-skilled jobs. The move strengthens UCB's U.S. footprint as it scales production for its high-growth immunology portfolio. Full story: https://gethealthbrief.com/story/ucb-atlanta-2b-manufacturing-investment ### UCB Announces $2B Biopharma Manufacturing Expansion in Suburban Atlanta 2026-03-24 23:50:49 · Sector: supply · Sentiment: Positive · Impact: 6/10 · Sources: 2 Belgian biopharmaceutical leader UCB has committed $2 billion to construct a new state-of-the-art manufacturing facility in suburban Atlanta, Georgia. The project is expected to create 330 high-skilled jobs and significantly bolster the region's growing life sciences ecosystem. Full story: https://getsupplybrief.com/story/ucb-2-billion-investment-atlanta-manufacturing-plant ### UCB to Invest $2B in Atlanta Biopharma Hub, Adding 330 Specialized Jobs 2026-03-24 23:50:45 · Sector: hr · Sentiment: Positive · Impact: 6/10 · Sources: 2 Belgian biopharma leader UCB is committing $2 billion to a new manufacturing facility in suburban Atlanta, creating 330 high-skilled positions. This investment underscores Georgia's rising status as a premier life sciences hub and highlights the intensifying competition for technical talent in the Southeast. Full story: https://gethrbrief.com/story/ucb-atlanta-biopharma-investment-2026 ### Antengene Eyes 2026 Profitability Following Landmark TCE Out-Licensing Deal 2026-03-20 14:54:16 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 3 Antengene Corporation has reported its 2025 full-year financial results, highlighted by the first successful out-licensing of its proprietary T-cell engager (TCE) platform. This strategic milestone validates the company's R&D capabilities and establishes a clear path toward projected profitability by 2026. Full story: https://getbiobrief.com/story/antengene-2025-results-tce-licensing-profitability ### UCB and Antengene Ink $1.1B Deal for CD19 Bispecific in Autoimmune Pivot 2026-03-04 00:38:57 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2 Antengene has granted UCB exclusive global rights to ATG-201, a CD19/CD3 bispecific T-cell engager, in a deal worth up to $1.18 billion. The partnership leverages Antengene's AnTenGager platform to target B-cell-driven autoimmune diseases, marking a major strategic expansion for both firms. Full story: https://getbiobrief.com/story/ucb-antengene-atg201-licensing-deal-autoimmune ### UCB and Antengene Ink $1.2B Deal for Bispecific T-Cell Engager ATG-201 2026-03-04 00:38:23 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2 UCB has secured exclusive global rights to Antengene's ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases. The agreement includes $80 million in upfront payments and potential milestones exceeding $1.1 billion, validating Antengene's AnTenGager platform. Full story: https://gethealthbrief.com/story/ucb-antengene-atg201-licensing-deal --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.